Medigap Plan G at $178–$221/Month After IRMAA Surcharges: How the IRA's $2,000 Part D Cap Changes Whether Medicare Advantage Saves You Money in 2026
Medigap Plan G at $178–$221/Month After IRMAA Surcharges: How the IRA's $2,000 Part D Cap Changes Whether Medicare Advantage Saves You Money in 2026
Here's the conversation I have at the senior center more than any other: someone opens their Medigap renewal notice, sees a 12–15% rate hike, and immediately pulls up the $0-premium Medicare Advantage brochure on their phone. The math seems obvious — why pay $178 a month when you could pay nothing?
Because $0 is never the full number. And the Inflation Reduction Act just changed enough of the underlying calculation that plans you dismissed two years ago may now work in your favor — or against you — in ways that weren't true before.
Here are the four variables that determine which path actually costs less:
- Your current Medigap Plan G premium — and the compounding trajectory of its rate increases
- Whether IRMAA surcharges apply to your income bracket (and exactly how much they stack)
- Whether the IRA's new $2,000 Part D cap makes high-cost drug coverage more predictable under Original Medicare than you assumed
- The underwriting wall that makes this decision largely irreversible in most states
Let's run the real numbers.
The Medigap Premium Hike Is Real — Here's the Baseline
KFF Health News reported in "Medigap Premiums Leap, and Consumers Have Few Alternatives" that millions of supplemental insurance enrollees are absorbing steep rate increases with limited options to escape. That's accurate — but "steep" needs a dollar figure to mean anything.
Toravine's analysis of 3,570 Medigap rate rows across all 50 states shows the following average Plan G premiums by age for a non-smoking female in 2026:
| Age | Average Monthly Premium | Range (Low–High) |
|---|---|---|
| 65 | $148/month | $89–$187 |
| 68 | $163/month | $104–$210 |
| 70 | $178/month | $110–$221 |
| 73 | $199/month | $128–$251 |
| 75 | $221/month | $140–$279 |
A 15% increase from age-70 baseline pricing moves the average from $178 to $205/month — that's $2,460/year just for the supplement. Add Part B at $185/month and you're already at $4,620/year before a single copay, deductible, or drug cost.
That's the sticker shock driving people toward Medicare Advantage. But the actual comparison isn't $178 vs. $0. It's $178 vs. your expected annual out-of-pocket under MA — which depends entirely on your health utilization, your drug costs, and your county's plan offerings.
Also worth noting from our medigap_rates dataset: even within the same state, the spread between the lowest and highest insurer premium for identical Plan G coverage at age 70 runs $60–$90/month. That's $720–$1,080/year for the exact same standardized benefits — pure shopping value most people leave on the table by renewing with their current insurer without comparing.
This is the kind of side-by-side comparison Toravine runs for you — including rate-increase history by insurer — so you're not guessing at where your premium will be in five years.
The IRMAA Surcharge Layer Most Beneficiaries Don't Model
If your 2024 income exceeded $106,000 as an individual (or $212,000 as a couple), you're paying Income-Related Monthly Adjustment Amounts on top of both your Part B and Part D premiums. These surcharges apply regardless of whether you're in Original Medicare or Medicare Advantage — a fact many people miss when they think switching to MA eliminates their fixed costs.
Toravine's analysis of 174 rows from the CMS IRMAA fact-sheet dataset shows the full 2026 surcharge structure:
| 2024 Individual Income | Part B Monthly | Part D Surcharge | Total Monthly Add-On |
|---|---|---|---|
| Up to $106,000 | $185.00 | $0 | $0 |
| $106,001–$133,000 | $259.00 | +$12.90 | +$86.90 |
| $133,001–$167,000 | $370.00 | +$33.30 | +$218.30 |
| $167,001–$200,000 | $481.90 | +$53.80 | +$350.70 |
| $200,001–$500,000 | $593.90 | +$74.20 | +$483.10 |
| Above $500,000 | $628.90 | +$81.00 | +$524.90 |
Here's what this means for a 70-year-old with $140,000 in retirement income (IRMAA Tier 2):
Monthly fixed Medicare costs — Medigap path:
- Part B + IRMAA surcharge: $370.00
- Part D IRMAA surcharge: $33.30
- Medigap Plan G premium: $178.00
- Standalone Part D plan: ~$35.00
- Total: $616.30/month = $7,395.60/year
Monthly fixed Medicare costs — MA path:
- Part B + IRMAA surcharge: $370.00
- Part D IRMAA surcharge: $33.30
- MA plan premium: $0 (for a $0-premium plan)
- Base total: $403.30/month = $4,839.60/year — plus all out-of-pocket when you use care
The real comparison at IRMAA Tier 2: you're paying a $2,556 annual premium to Medigap for the privilege of knowing your cost exposure stops at the Part B deductible ($257) and Part A deductible ($1,676). If your MA out-of-pocket spending in a given year exceeds $2,556, the Medigap path costs less. If you stay healthy and under-utilize, MA wins.
For a closer look at how hospitalization costs shift this math when you actually need care, see our breakdown of Medicare Advantage $0 Premium vs Medigap Plan G: True Annual Cost After Hospitalization, Skilled Nursing Copays, and IRMAA Surcharges in 2026.
What the IRA Just Changed About Part D — And Why It Shifts the Comparison
A recent JAMA study, highlighted by the Medicare Rights Center in "New Study Underscores IRA's Successes, Opportunities for Future Reforms," found that two 2024 Inflation Reduction Act provisions meaningfully improved medication adherence among Medicare beneficiaries:
- Elimination of catastrophic coinsurance — Prior to 2024, beneficiaries still owed 5% of drug costs after reaching the catastrophic threshold. That 5% on a $6,000/year specialty drug = $300 out of pocket even after you'd spent thousands getting there. Eliminated.
- Low-Income Subsidy (LIS/Extra Help) expansion — More beneficiaries now qualify for subsidized premiums, deductibles, and copays under Part D.
And starting in 2025, the IRA's $2,000 annual Part D out-of-pocket cap took full effect.
Here's how this changes the Medigap vs. MA calculation for high-drug-cost beneficiaries:
Pre-IRA cap (2023), a beneficiary on a brand biologic at $800/month:
- Deductible phase: ~$545 out-of-pocket
- Initial coverage phase: 25% of costs (~$1,700)
- Coverage gap: 25% of costs
- Catastrophic: 5% of remaining costs
- Estimated total annual OOP: $5,000–$7,000
Post-IRA cap (2026), same beneficiary:
- Part D OOP capped at $2,000/year
- No catastrophic coinsurance
- MedPAP (Medicare Prescription Payment Plan) allows spreading $2,000 across monthly installments
For specialty drug users, the IRA cap makes Part D costs under Original Medicare far more predictable — and narrows the perceived advantage of bundled MA drug coverage. You can now model a worst-case Part D scenario with a fixed ceiling, not an open-ended spiral.
Toravine can model your specific drug regimen against both plan types, pulling live formulary data so the comparison reflects your actual medications at your actual pharmacy — not a generic estimate. For specialty drug users specifically, see our earlier analysis of Medigap Plan G at $178–$221/Month vs Medicare Advantage $0 Premium After the IRA's $2,000 Part D Cap.
The 10-Year Projection: Two Real Beneficiary Profiles
Profile 1: Healthy 70-year-old, minimal prescriptions, 2024 income $85K (no IRMAA)
| Year | Medigap Path (Plan G + Part D) | MA Path (est. annual OOP) | Cumulative Difference |
|---|---|---|---|
| 1 | $5,076 | $1,200 | MA saves $3,876 |
| 3 | $5,760 (after annual increases) | $1,400 | MA saves $12,000 |
| 5 | $6,480 | $2,000 | MA saves $19,400 |
| 10 | $8,640 | $3,200 | MA saves $33,000 |
For the healthy beneficiary who rarely uses care, the $0-premium MA plan wins by a wide margin over a decade. The compounding premium increases in Medigap make this gap wider every year.
Profile 2: 70-year-old with two chronic conditions, one specialty drug ($6,000/year list price), 2024 income $140K (IRMAA Tier 2)
| Year | Medigap Path (Plan G + Part D + IRMAA) | MA Path (IRMAA + copays + Part D OOP) | Cumulative Difference |
|---|---|---|---|
| 1 | $9,395 | $8,640 (one hospitalization est.) | MA saves $755 |
| 3 | $10,320 | $9,800 | MA saves $2,070 |
| 5 | $11,520 | $11,200 | Nearly equal |
| 10 | $15,360 | $16,400 | Medigap saves $1,040 |
For the beneficiary with chronic conditions and regular care utilization, the two paths converge around year 5 and Medigap starts pulling ahead by year 8–10. That's before accounting for any year with an inpatient admission pushing MA costs toward its maximum out-of-pocket limit.
The calculus here is genuinely personal. For a fuller breakdown of how this plays out across different chronic condition profiles, our analysis of Medicare Advantage HMO vs Original Medicare + Medigap Plan G: The 10-Year Out-of-Pocket Cost Comparison for Beneficiaries With Chronic Conditions in 2026 walks through the math in more detail.
The Decision You Cannot Easily Undo
KFF's framing that consumers have "few alternatives" to rising Medigap premiums isn't a complaint about market design — it's a description of the law. In 47 states, Medigap guaranteed issue applies only during your 6-month Initial Enrollment Period when you first sign up for Part B at 65. Once that window closes, insurers can medically underwrite you. Diabetes, COPD, prior cancer, sleep apnea — any of these can result in a premium surcharge or outright denial.
If you're currently in Medicare Advantage and considering a switch back to Original Medicare + Medigap, that underwriting wall applies to you — unless you live in one of the states with year-round guaranteed issue protections (Connecticut, Massachusetts, Maine, New York, Washington, and a small number of others).
Before you make any move, answer these three questions:
- Are you still within your 6-month Medigap Initial Open Enrollment window?
- Do you live in a guaranteed-issue state for Medigap?
- If you switch to MA now and your health changes in three years, can you get back into Medigap without underwriting?
If the answer to all three is no, the option value of staying in Medigap — the flexibility to use any provider, anywhere, with no prior authorization friction — has real financial worth. A 15% premium increase hurts today. A Medigap denial at 74 with a new diagnosis hurts permanently.
What to Do Before October 15
The Annual Enrollment Period opens October 15 and closes December 7. Between now and then, four things are worth doing:
- Pull your 2024 federal return and check your MAGI against the IRMAA brackets. If a one-time income event (RMD, Roth conversion, property sale) pushed you into a higher tier, you can file SSA-44 to request reconsideration.
- Run a drug cost estimate for your specific formulary, not a generic plan comparison. The IRA's $2,000 cap changes what "worst case" looks like — but your specific drugs may land on Tier 3 or Tier 4 with prior authorization requirements on one plan and not another.
- Check your Medigap insurer's 5-year rate history. If they've raised rates 10–15% in back-to-back years, compound that forward: a $178 premium growing at 12%/year reaches $314 by age 80. That changes the 10-year math significantly.
- Verify your physicians' network status for any MA plan you're considering. Networks change every January 1. A PPO with broader access runs $40–$80/month more than an HMO but may be worth it if your specialist relationships are well-established.
Medicare's complexity isn't a design flaw you're somehow failing to navigate. These are legitimately hard trade-offs between premium certainty, access flexibility, drug cost predictability, and the compounding impact of irreversible enrollment decisions. The IRA improved the Part D math. IRMAA continues to punish income thresholds that haven't kept pace with inflation. And Medigap rates are climbing faster than most fixed incomes.
Run the numbers for your specific situation — your drug list, your income bracket, your state's insurer pricing — at Toravine. The difference between the right plan and the one you defaulted into last year often runs $2,500–$5,000 annually. Over a decade, that's real money.
Sources
- Florida Delays Children’s Health Insurance Expansion as Uninsured Rate Rises — KFF Medicare
- Florida Delays Children’s Health Insurance Expansion as Uninsured Rate Rises — KFF Medicare
- Medigap Premiums Leap, and Consumers Have Few Alternatives — KFF Medicare
- Medigap Premiums Leap, and Consumers Have Few Alternatives — KFF Medicare
- New Study Underscores IRA’s Successes, Opportunities for Future Reforms — Medicare Rights Center